ARL2BPP5

Across TCGA pan-cancer cohorts, ARL2BPP5 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated ARL2BPP5 data layer.

The strongest signal is observed in thyroid carcinoma (THCA), where higher ARL2BPP5 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL2BPP5 expression acts as an unfavorable survival marker.

THCA, UCS, and PAAD are the cancer types where ARL2BPP5 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Tertile	All	0.075	0.830	<.001	117	view →
UCS	OS	Tertile	All	0.001	0.690	<.001	108	view →
PAAD	OS	Tertile	All	0.112	0.613	<.001	72	view →
STAD	DFS	Tertile	II,III,IV	0.365	0.720	<.001	72	view →
ESCA	OS	Tertile	All	0.205	0.911	<.001	72	view →
ACC	OS	Tertile	All	0.113	0.822	<.001	63	view →
BLCA	DFS	Tertile	III,IV	0.105	0.575	<.001	54	view →
UCEC	OS	Tertile	All	0.829	0.930	.001	42	view →
BRCA	DFS	Tertile	II,III,IV	0.813	0.942	.006	39	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ARL2BPP5–THCA (DFS)

Open the THCA breakdown →